

Resource Summary Report

Generated by PRECISE-TBI on Aug 1, 2026

COST

RRID:SCR_014098

Type: Tool

Proper Citation

COST (RRID:SCR_014098)

Resource Information

URL: http://www.nitrc.org/projects/cost_unc/

Proper Citation: COST (RRID:SCR_014098)

Description: A tool that implements a graph-based connectivity assessment method. This method uses a multi-directional graph propagation method applied to sampled orientation distribution function (ODF), which can be computed directly from the original diffusion imaging data.

Abbreviations: COST

Synonyms: Connectivity Orientation Spherical distribution Tool

Resource Type: software resource, software application, data processing software, image analysis software

Keywords: software tool, connectivity assessment, image analysis software

Resource Name: COST

Resource ID: SCR_014098

Record Creation Time: 20220129T080319+0000

Record Last Update: 20260731T042903+0000

Ratings and Alerts

No rating or validation information has been found for COST.

No alerts have been found for COST.

Data and Source Information

Usage and Citation Metrics

We found 4519 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Farmakis IT, et al. (2025) Healthcare resource utilisation and associated costs after low-risk pulmonary embolism: pre-specified analysis of the Home Treatment of Pulmonary Embolism (HoT-PE) study. *Clinical research in cardiology : official journal of the German Cardiac Society*, 114(2), 168.

Mancuso M, et al. (2025) Cost-effectiveness of neuropsychological rehabilitation for acquired brain injuries: Update of Stolwyk et al.'s (2019) review. *Journal of neuropsychology*, 19(1), 115.

Muniyandi M, et al. (2025) Evaluating the cost-effectiveness of Cy-Tb for LTBI in India: a comprehensive economic modelling analysis. *International health*, 17(3), 259.

Paulissen JHJ, et al. (2025) Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy. *Advances in therapy*, 42(1), 322.

Brännström M, et al. (2025) The costs per live birth after uterus transplantation: results of the Swedish live donor trial. *Human reproduction (Oxford, England)*, 40(2), 310.

Rink JS, et al. (2025) Mobile stroke units services in Germany: A cost-effectiveness modeling perspective on catchment zones, operating modes, and staffing. *European journal of neurology*, 32(1), e16514.

Campbell HE, et al. (2025) Evaluating the Cost-Effectiveness of Antenatal Screening for Major Structural Anomalies During the First Trimester of Pregnancy: A Decision Model. *BJOG : an international journal of obstetrics and gynaecology*, 132(5), 638.

Lefèvre G, et al. (2025) Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. *PloS one*, 20(1), e0313694.

Wagner GJ, et al. (2025) Study protocol for a hybrid implementation-effectiveness trial of Game Changers for Cervical Cancer Prevention in Uganda. *PloS one*, 20(1), e0317491.

Kongmalai T, et al. (2025) Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand. *PharmacoEconomics - open*, 9(1), 69.

Settumba S, et al. (2025) Provider costs of treating opioid dependence with extended-release buprenorphine in Australia. *Drug and alcohol review*, 44(1), 179.

Atreja N, et al. (2025) US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life

years and health years in total. *Journal of comparative effectiveness research*, 14(1), e240163.

Geyer D, et al. (2025) Depth of emotional experiencing and outcome in therapy with young people. *Psychology and psychotherapy*, 98(2), 308.

Wang D, et al. (2025) Ir-O-Mn embedded in porous nanosheets enhances charge transfer in low-iridium PEM electrolyzers. *Nature communications*, 16(1), 181.

Shinohara A, et al. (2025) Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data. *Scientific reports*, 15(1), 267.

Han L, et al. (2025) Study on the spatial and temporal evolution of ecosystem service value based on land use change in Xi'an City. *Scientific reports*, 15(1), 66.

Stalter L, et al. (2025) Data Resource Profile: The Veterans Affairs-Health and Retirement Study Aging Veteran Cohort. *Journal of the American Geriatrics Society*, 73(6), 1947.

Okeahialam N, et al. (2025) Effects of strategies to tackle racism experienced by healthcare professionals: a systematic review. *BMJ open*, 15(1), e091811.

Shiyanbola OO, et al. (2025) Optimizing diabetes management interventions for Black and Hispanic adults using the multiphase optimization strategy: Protocol for a randomized mixed methods factorial trial. *Contemporary clinical trials*, 149, 107804.

Li L, et al. (2025) Association between volume and cost in low-resection volume regions: a population-level study on pancreatoduodenectomy for pancreatic cancer patients. *ANZ journal of surgery*, 95(3), 377.